Frontlight ResearchEarly access
Taking peoplePhase 1
A Clinical Study Evaluating the Safety, Tolerability, and Initial Efficacy of JWK008 in Patients With Mucopolysaccharidosis Type I
Key facts
- Who runs it
- West China Hospital
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 6 people, planned
- Started
- 22 Jul 2024
- Expected to end
- 22 Jun 2029
- Type of study
- Interventional
- Treatments tested
- JWK008 Single intravenous infusion administration
- Record updated
- 25 July 2024
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- Age≥ 18 years old
- Diagnosis of MPS type I
- Be able to understand the purpose, content, and possible risks of this clinical study, voluntarily participate in and sign the informed consent form
- If the subject is female, her sexual partner must agree to use reliable contraception until 2 consecutive tests of vector sequence in the blood are negative; If the subject is male, the subject agrees to use reliable contraception until the semen sample is negative for 2 consecutive tests of the vector sequence
- Magnetic resonance imaging (MRI) of the liver mass read by the radiologist is negative
Who cannot take part
- Known to be unresponsive to ERT; or those who have been treated with intrathecal or intravenous laronidase and have serious adverse reactions, such as significant infusion-related reactions (IARs) or anaphylactic shock
- Has contraindications for Corticosteroids
- Current treatment with systemic (intravenous or oral) immunomodulators or steroid use (topical treatments such as asthma or eczema are allowed)
- Previously received gene therapy or participated in interventional clinical studies within the past 12 weeks
- The researcher believes that the subject is not suitable to participate in any concurrent clinically significant major diseases or other situations in the study
- Have a history of chronic infections or other chronic diseases that researchers believe pose an unacceptable risk
- Active severe infection or any other significant accompanying, uncontrolled medical condition(except for those caused by MPS I), including but not limited to kidney, liver, blood, gastrointestinal, endocrine, lung, nervous system, brain or mental illness, alcoholism, drug dependence, or any psychological disorder assessed by the researcher that may interfere with adherence to experimental protocol procedures or tolerance to JWK008 injection
- History of active malignancy within the past 5 years (non-melanotic skin cancer or carcinoma in situ of the cervix is allowed)
- Serum AAV5 neutralizing antibody titer is greater than 1:100
- When filtering, one of the following situations exists:; Hepatitis B surface antigen (HBsAg) is positive, and the copy number of hepatitis B virus deoxyribonucleic acid (HBV-DNA) is>the upper limit of normal value (ULN); Hepatitis C virus antibody (HCV-Ab) is positive, and the copy number of hepatitis C virus ribonucleic acid (HCV-RNA) is>ULN; Receiving antiviral treatment for hepatitis B or C; The human immunodeficiency virus (HIV) test is positive and the CD4+T lymphocyte count is ≤ 200/mm3
- Abnormal laboratory values considered clinically significant (ALT and/or AST >3× upper limit of normal (ULN), total bilirubin > 1.5× ULN, serum creatinine > 1.5× ULN, etc.)
- Has contraindications for lumbar puncture
- Circulating alpha-fetoprotein (AFP) is elevated or abnormal
- Pregnant or lactating females
- Unable or unwilling to comply with the visit and study evaluation schedule described in the clinical protocol
This trial is currently available in China.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study is a single-center, single-arm, non-randomized, open-label, non controlled, dose-escalation, prospective clinical trial designed to assess the safety, tolerability, and preliminary efficacy of JWK008 injection in patients with MPS I.
The group in the trial
- JWK008 injectionTreatment being tested
The participants will be given 5.0×10\^12vg/kg or 2.0×10\^13vg/kg body weight of JWK008
Treatment: JWK008 Single intravenous infusion administration
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Clinical Study Evaluating the Safety, Tolerability, and Initial Efficacy of JWK008 Given by a Single Intravenous Infusion in Patients With Mucopolysaccharidosis Type I
- Record updated
- 25 July 2024